Wellcome Sanger Institute
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research
The companies are working together on cellular medicines to boost, replace or repair biological functions
Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa
The company is planning to submit regulatory applications for the candidate by the end of the year
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn
The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study
BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use
Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers
LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab
The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer
Eli Lilly announces $3bn expansion to US injectables manufacturing facility
The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines
Sanofi unveils plans to build €1bn insulin production base in China
The site will focus on serving the insulin medication needs of local diabetic patients
BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use
Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth
BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer
Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth
Common antidiabetic drug metformin found to slow growth of precancerous cells
The findings suggest that the drug could be used to manage squamous oesophageal cancer risk
Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials
It is hoped that a once-weekly treatment option could improve adherence rates